{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-085446","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.842919+00:00","generated_at":"2026-06-24T05:19:39.223565+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kiniksa licenses vixarelimab to Genentech for $100M upfront; Q2 ARCALYST rev $27M","bullets":["Genentech gets worldwide rights to vixarelimab; Kiniksa receives $100M upfront/near-term and up to $600M in milestones plus tiered royalties.","ARCALYST Q2 2022 net revenue $27.0M (vs. $7.7M Q2 2021); full-year 2022 guidance reaffirmed at $115-130M.","Q2 net loss narrowed to $20.0M (vs. $41.6M), with cash $138.2M and no debt; cash runway into 2025 after deal close.","Phase 2b vixarelimab trial in prurigo nodularis screening complete; data disclosure delayed beyond H2 2022.","Proceeds to fund cardiovascular pipeline expansion; ~20 additional ARCALYST sales reps planned in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-085446","json":"https://secwatch.observer/filing/0001104659-22-085446.json","markdown":"https://secwatch.observer/filing/0001104659-22-085446.md","text":"https://secwatch.observer/filing/0001104659-22-085446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922085446/0001104659-22-085446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922085446/tm2222182d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:19:39.223565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}